DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2007-D-0369]

Product-Specific Guidance for Levonorgestrel; Intrauterine Device; Revised Draft Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a revised draft guidance for industry, entitled “Draft Guidance for Levonorgestrel.” The revised draft guidance, when finalized, will provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for a levonorgestrel intrauterine device.

DATES: Submit either electronic or written comments on the draft guidance by [INSERT DATE 60 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER] to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.

ADDRESSES: You may submit comments as follows:

Electronic Submissions

Submit electronic comments in the following way:

- Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential
information that you or a third party may not wish to be posted, such as medical
information, your or anyone elseʼs Social Security number, or confidential
business information, such as a manufacturing process. Please note that if you
include your name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on

- If you want to submit a comment with confidential information that you do not
wish to be made available to the public, submit the comment as a written/paper
submission and in the manner detailed (see “Written/Paper Submissions” and
“Instructions”).

*Written/Paper Submissions*

Submit written/paper submissions as follows:

- Mail/Hand delivery/Courier (for written/paper submissions): Dockets
  Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers
  Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA
  will post your comment, as well as any attachments, except for information
  submitted, marked and identified, as confidential, if submitted as detailed in
  “Instructions.”

*Instructions:* All submissions received must include the Docket No. FDA-2007-D-0369 for
“Product-Specific Guidance for Levonorgestrel; Intrauterine Device.” Received comments
will be placed in the docket and, except for those submitted as “Confidential Submissions,”
will be publicly viewable at https://www.regulations.gov or at the Dockets Management Staff
office between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).
Submit written requests for single copies of the draft guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance.

FOR FURTHER INFORMATION CONTACT: Wendy Good, Center for Drug Evaluation and Research (HFD-600), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 4730, Silver Spring, MD 20993-0002, 301-796-5850.

SUPPLEMENTARY INFORMATION:

I. Background

In the Federal Register of June 11, 2010 (75 FR 33311), FDA announced the availability of a guidance for industry entitled “Bioequivalence Recommendations for Specific Products,” which explained the process that would be used to make product-specific guidances available to the public on FDA’s website at https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs.

As described in that guidance, FDA adopted this process to develop and disseminate product-specific guidances and to provide a meaningful opportunity for the public to consider and comment on the guidances. This notice announces the availability of a revised draft guidance on a generic levonorgestrel intrauterine device.

FDA initially approved new drug application 21225 for MIRENA (levonorgestrel intrauterine device) in December 2000. In April 2014, FDA issued a draft product-specific guidance for industry on a generic levonorgestrel intrauterine device. FDA subsequently withdrew that draft guidance in October 2014 because the recommended in vitro studies lacked adequate specificity. We are now issuing a revised draft guidance for industry on a generic levonorgestrel intrauterine device (“Draft Guidance on Levonorgestrel”) with
recommendations for a combination of two studies, in vitro testing and an in vivo/ex vivo study, to demonstrate BE.

In December 2015, Bayer HealthCare LLC, manufacturer of the reference listed drug MIRENA, submitted a citizen petition requesting that FDA withhold approval of any ANDA for a generic version of MIRENA unless certain conditions were satisfied, including conditions related to demonstrating BE ((Docket No. FDA-2015-P-4600), available at https://www.regulations.gov). FDA is reviewing the issues raised in that petition. However, FDA will consider any comments received on the guidance entitled, “Draft Guidance on Levonorgestrel,” before responding to the citizen petition.

The revised draft guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The revised draft guidance, when finalized, will represent the current thinking of FDA on the design of BE studies to support ANDAs for a levonorgestrel intrauterine device. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.

II. Electronic Access

Persons with access to the internet may obtain the draft guidance at either


Lowell J. Schiller,

Principal Associate Commissioner for Policy.

[FR Doc. 2020-01072 Filed: 1/22/2020 8:45 am; Publication Date: 1/23/2020]